Displaying drugs 10401 - 10425 of 12433 in total
Human Menstrual Blood-derived Stem Cells
Stem cells are self-renewing and proliferate without differentiation, with the two major groups being embryonic stem cells (ESCs) and adult stem cells (ASC). Differentiation occurs under different conditions into different cell types. ESCs are from the inner cell mass of blastocysts while ASCs are deposited into adult tissues with restricted...
Investigational
Matched Description: … differentiation potency but also a lack of tumorigenicity. ... ethical issues that may come from obtaining stem cells of the embryonic kind. ... These cells possess a high rate of proliferation and multi-lineage differentiation potency. …
Oportuzumab monatox
VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor...
Investigational
Matched Description: … VB4-845 is studied in the treatment of certain types of head and neck cancer. ... epithelial origin and a truncated portion of Pseudomonas exotoxin A. ... cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of …
CHGN111
CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative stress. It...
Investigational
Matched Description: … Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which ... results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative ... CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. …
Sulforaphane
Sulforaphane is under investigation for the treatment of Autism Spectrum Disorder. It is a naturally occurring isothiocyanate found in high concentration in a variety of broccoli.
Investigational
Matched Description: … Sulforaphane is under investigation for the treatment of Autism Spectrum Disorder. ... It is a naturally occurring isothiocyanate found in high concentration in a variety of broccoli. …
GS-9191
GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
Investigational
Matched Description: … Topical Ointment (GS-9191) for the Treatment of Genital Warts). ... GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental …
Ecraprost
Ecraprost is under investigation in clinical trial NCT00059657 (Efficacy/safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease).
Investigational
Matched Description: … Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease). ... Ecraprost is under investigation in clinical trial NCT00059657 (Efficacy/safety of Ecraprost in Lipid …
XMT-2056
XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.
Investigational
Matched Description: … with a stimulator of interferon genes (STING) agonist payload. ... XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated …
HTPEP-001
HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.
Investigational
Matched Description: … It is being investigated for the treatment of fibrosis.[A263527] ... HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta …
EPC2407
EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. These tumors
include the frequently occurring cancers of the lung,...
Investigational
Matched Description: … EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of ... These tumors
include the frequently occurring cancers of the lung, gastrointestinal tract, ovaries, ... It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized …
VSF-173
VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive...
Investigational
Matched Description: … It is developed for the treatment of excessive sleepiness. ... that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of ... Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness. …
Cytisine
Cytisine is an alkaloid naturally derived from the Fabaceae family of plants including the genera Laburnum and Cytisus. Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy. Also known as baptitoxine or sophorine, cytisine has been used as...
Experimental
Matched Description: … similar efficacy to varenicline, but at a fraction of the cost. ... Cytisine is a partial nicotinic acetylcholine agonist with a half-life of 4.8 hours. ... Cytisine is an alkaloid naturally derived from the Fabaceae family of plants including the genera Laburnum …
Cusatuzumab
CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival. An overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety...
Investigational
Matched Description: … An overexpression of CD70 can result in the proliferation of malignant cells and has been documented ... in a variety of solid and hematological malignancies. ... CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in …
CCX915
CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and...
Investigational
Matched Description: … trial for the treatment of Multiple Sclerosis and Neurologic Disorders. ... CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical ... The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis …
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
Matched Description: … It is developed for the treatment of solid tumors. ... 012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of ... ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties …
COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’ The vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity.
Investigational
Matched Description: … the COVID-19 AP TP Vaccine for ‘proof of concept.’ ... As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for ... macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of …
OTL-201
OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.
Investigational
Matched Description: … It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase ... hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of …
Reloxiliase
Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.
Investigational
Matched Description: … It is being investigated for the treatment of hyperoxaluria.[A258823] ... Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme …
Resiniferatoxin
Resiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission of physiological pain).
Investigational
Matched Description: … primary afferent sensory neurons involved in nociception (the transmission of physiological pain). ... naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of …
IPI-549
IPI-549 is under investigation in clinical trial NCT03795610 (Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma).
Investigational
Matched Description: … IPI-549 is under investigation in clinical trial NCT03795610 (Window of Opportunity Study of IPI-549 …
Cediranib
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … It is being developed clinically as a once-daily oral therapy for the treatment of cancer. ... quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of …
TZP-102
TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).
Investigational
Matched Description: … of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis). ... TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration …
R411
R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to...
Investigational
Matched Description: … R411 is a non-steroid oral medicine for the treatment of asthma. ... It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory ... antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of …
RTA 744
RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current...
Investigational
Matched Description: … Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they ... anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of …
DDP733
DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD). It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in...
Investigational
Matched Description: … the motility of the GI tract). ... It is a partial agonist of the serotonin type 3 receptor (5-HT3). ... Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal ( …
AEG35156
A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome...
Investigational
Matched Description: … AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP) ... , a pivotal inhibitor of apoptosis that is overexpressed in many tumors. ... This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs …
Displaying drugs 10401 - 10425 of 12433 in total